Term
|
Definition
Mab
Block IL-6 receptor
Rheumatoid Arthritis
Marketed |
|
|
Term
|
Definition
Recombinant Protein
Therapeutic Delivery of Tissue Plasminogen Activator
Acute MI/Stroke
Marketed |
|
|
Term
|
Definition
Recombinant
Glucagon-like peptide-1 receptor agonist
T2DM
Phase 3 |
|
|
Term
|
Definition
T-cell therapy
Induction of anti-cancer immune response
Leukemia/Myeloma
Phase 1/2 |
|
|
Term
|
Definition
Recombinant Protein
IL-1 Receptor Antagonist
Rheumatoid Arthritis
Marketed |
|
|
Term
|
Definition
Recombinant Engineered Protein
Erythropoiesis Stimulation
Anemia of Kidney disease/chemo
Marketed |
|
|
Term
|
Definition
HTN vaccine
Block Angiotensin-1
HTN
pre-clinical |
|
|
Term
|
Definition
Mab
Decrease VEGF
Glioblastoma and Cancer
Marketed |
|
|
Term
|
Definition
Mab
Targets CD20
Chronic leukemia
Marketed |
|
|
Term
|
Definition
Mab
Decrease Beta-amyloid
Alzheimers
Phase 3 |
|
|
Term
|
Definition
Mab
Decrease B-lymphocyte stimulator
Lupus
Marketed |
|
|
Term
|
Definition
Mab
CD30-directed antibody toxin
Hodgkin's lymphoma
accelerated approval |
|
|
Term
|
Definition
Engineered autologous dendritic cells
Precent mucin-1 antigen
Ovarian cancer vaccine
Phase 2/3 |
|
|
Term
|
Definition
Recombinant Protein
Tolerance induction to beta-cell antigen
T1DM vaccine
Phase 3 |
|
|
Term
|
Definition
Mab
Block EGF Receptor
Colorectal Cancer
Marketed |
|
|
Term
|
Definition
Synthetic peptide analog
B-cell progenitor cells
T1DM and T2DM
Phase 2 |
|
|
Term
|
Definition
Recombinant
Decrease VEGF
Wet age macular degeneration
Marketed |
|
|
Term
|
Definition
Mab
Insulin-like GF 1
Ewing Sarcoma
Phase 1/2 |
|
|
Term
|
Definition
Antisense
Inhibit cytomegalovirus
CMV retinitis
Withdrawn from market |
|
|
Term
|
Definition
Recombinant peptide
Parathyroid hormone receptor
Osteoporosis
Marketed |
|
|
Term
|
Definition
Antisense
Blocks BCL-2
Non-Hodgkin's Lymphoma
Phase 2 |
|
|
Term
|
Definition
Angiogenic gene therapy
FGF-4 Expression
Coronary Artery Disease
Phase 3 |
|
|
Term
|
Definition
Cell Therapy
Irradiated, engineered prostate cells
Advanced Prostate Cancer
Phase 2 |
|
|
Term
|
Definition
Mab
Decrease TNF-alpha
Rheumatoid Arthritis
Marketed |
|
|
Term
|
Definition
Mab
Decrease interleukin 1-beta
Cryoporin-associated periodic syndrome
Marketed |
|
|
Term
|
Definition
Recombinant
GM-CSF augmentation
Chemotherapy/Bone Marrow xplant
Marketed |
|
|
Term
|
Definition
Mab
decrease VEGF
Wet age-related macular degeneration
Marketed |
|
|
Term
|
Definition
Oncolytic Virus Gene Therapy
Infect Cancer Cells
Head and Neck Cancer
Phase 2 |
|
|
Term
|
Definition
Ligand-Fc Fusion Protein
Block CD80/86 dendritic cells
RA
Marketed |
|
|
Term
|
Definition
Mesenchymal Adult Stem Cells
Tissue Repair
Graft vs Host/Crohns
Phase 3 |
|
|
Term
|
Definition
Mab
Decrease TNF-Alpha
Crohn's disease
Marketed |
|
|
Term
|
Definition
Mab
Targets CD20
Non-Hodgkin Lymphoma
Marketed |
|
|
Term
|
Definition
Mab
Block CD20
B-cell Chronic leukemia/MM
Phase 1/2 |
|
|
Term
|
Definition
Mab
Decrease Beta-amyloid
Alzheimer's Disease
Phase 3 |
|
|
Term
|
Definition
Recombinant Engineered Protein
Glucagon-like peptide-1 receptor agonist
T2DM
Marketed |
|
|
Term
|
Definition
Mab
RANK ligand inhibitor
Bone metastasis
Marketed |
|
|
Term
|
Definition
Mab
Decrease IgE
Asthma
Marketed |
|
|
Term
|
Definition
Mab
Activate cytotoxic t-cells
Melanoma
Marketed |
|
|
Term
|
Definition
Mab
Block t-cell IL-2 receptor
Transplant Rejection
Phase 2 |
|
|
Term
|
Definition
Mab-radioisotope conjugate
Targets CD20 w/ radiation
non-Hodgkin lymphoma
Marketed |
|
|
